Cargando…

Comparison of tumor‐informed and tumor‐naïve sequencing assays for ctDNA detection in breast cancer

Analysis of circulating tumor DNA (ctDNA) to monitor cancer dynamics and detect minimal residual disease has been an area of increasing interest. Multiple methods have been proposed but few studies have compared the performance of different approaches. Here, we compare detection of ctDNA in serial p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Santonja, Angela, Cooper, Wendy N, Eldridge, Matthew D, Edwards, Paul A W, Morris, James A, Edwards, Abigail R, Zhao, Hui, Heider, Katrin, Couturier, Dominique‐Laurent, Vijayaraghavan, Aadhitthya, Mennea, Paulius, Ditter, Emma‐Jane, Smith, Christopher G, Boursnell, Chris, Manzano García, Raquel, Rueda, Oscar M, Beddowes, Emma, Biggs, Heather, Sammut, Stephen‐John, Rosenfeld, Nitzan, Caldas, Carlos, Abraham, Jean E, Gale, Davina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10245040/ https://www.ncbi.nlm.nih.gov/pubmed/37161793 http://dx.doi.org/10.15252/emmm.202216505

Ejemplares similares

Longitudinal monitoring of disease burden and response using ctDNA from dried blood spots in xenograft models
por: Sauer, Carolin M, et al.
Publicado: (2022)

Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA
por: Hudecova, Irena, et al.
Publicado: (2022)

Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA
por: Gao, Meiling, et al.
Publicado: (2019)

Correlating Radiomic Features of Heterogeneity on CT with Circulating Tumor DNA in Metastatic Melanoma
por: Gill, Andrew B., et al.
Publicado: (2020)

ctDNA: An emerging neoadjuvant biomarker in resectable solid tumors
por: Abbosh, Christopher, et al.
Publicado: (2021)

Regulatory implications of ctDNA in immuno-oncology for solid tumors
por: Vellanki, Paz J, et al.
Publicado: (2023)

Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy
por: Khatami, Fatemeh, et al.
Publicado: (2018)

The feasibility of using mutation detection in ctDNA to assess tumor dynamics
por: Yi, Xin, et al.
Publicado: (2017)

Fragmentation patterns and personalized sequencing of cell‐free DNA in urine and plasma of glioma patients
por: Mouliere, Florent, et al.
Publicado: (2021)

The characteristics of ctDNA reveal the high complexity in matching the corresponding tumor tissues
por: Yang, Nong, et al.
Publicado: (2018)

Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer
por: Todenhöfer, Tilman, et al.
Publicado: (2018)

A mathematical model of ctDNA shedding predicts tumor detection size
por: Avanzini, Stefano, et al.
Publicado: (2020)

Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors
por: Zhao, Jianhua, et al.
Publicado: (2023)

Modeling the effect of spatial structure on solid tumor evolution and ctDNA composition
por: Rachman, Thomas, et al.
Publicado: (2023)

Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors
por: Smith, Christopher G., et al.
Publicado: (2020)

The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA
por: Liu, Binliang, et al.
Publicado: (2022)

Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer
por: Gale, D., et al.
Publicado: (2022)

A dual biomarker detection platform for quantitating circulating tumor DNA (ctDNA)
por: Cai, Chunyan, et al.
Publicado: (2018)

Clinical factors associated with circulating tumor DNA (ctDNA) in primary breast cancer
por: Zhou, Yidong, et al.
Publicado: (2019)

The diagnostic value of circulating tumor cells and ctDNA for gene mutations in lung cancer
por: Lyu, Mengyuan, et al.
Publicado: (2019)

Beyond finding druggable targets and tumor mutational burden: to measure heterogeneity by ctDNA
por: Liu, Zhichao, et al.
Publicado: (2020)

Tumor-Informed Approach Improved ctDNA Detection Rate in Resected Pancreatic Cancer
por: Watanabe, Kazunori, et al.
Publicado: (2022)

NRG1 fusions in breast cancer
por: Howarth, Karen D., et al.
Publicado: (2021)

Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden
por: Maia, Manuel Caitano, et al.
Publicado: (2017)

Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma
por: Azzi, Georges, et al.
Publicado: (2022)

Cerebrospinal fluid ctDNA and metabolites are informative biomarkers for the evaluation of CNS germ cell tumors
por: Takayasu, Takeshi, et al.
Publicado: (2020)

Next-Generation Sequencing Analysis of ctDNA for the Detection of Glioma and Metastatic Brain Tumors in Adults
por: Liang, Jianfeng, et al.
Publicado: (2020)

Individualized Mini-Panel Sequencing of ctDNA Allows Tumor Monitoring in Complex Karyotype Sarcomas
por: Braig, David, et al.
Publicado: (2022)

Blood, Toil, and Taxoteres: Biological Determinants of Treatment-Induced ctDNA Dynamics for Interpreting Tumor Response
por: Boniface, Christopher T., et al.
Publicado: (2022)

Utility of ctDNA in predicting relapse in solid tumors after curative therapy: a meta-analysis
por: Mittal, Abhenil, et al.
Publicado: (2023)

Investigate the application of postoperative ctDNA-based molecular residual disease detection in monitoring tumor recurrence in patients with non-small cell lung cancer——A retrospective study of ctDNA
por: Zhang, Xuefei, et al.
Publicado: (2023)

Effects of Collection and Processing Procedures on Plasma Circulating Cell-Free DNA from Cancer Patients
por: Risberg, Bente, et al.
Publicado: (2018)

Role of ctDNA in Breast Cancer
por: Sant, Marta, et al.
Publicado: (2022)

The Role of ctDNA in Gastric Cancer
por: Mencel, Justin, et al.
Publicado: (2022)

Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples
por: Gumà, Josep, et al.
Publicado: (2022)

Assessing the Impact of Circulating Tumor DNA (ctDNA) in Patients With Colorectal Cancer: Separating Fact From Fiction
por: Gabriel, Emmanuel, et al.
Publicado: (2018)

Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients
por: Marczynski, Gabriella Taques, et al.
Publicado: (2020)

The Promise of Circulating Tumor DNA (ctDNA) in the Management of Early-Stage Colon Cancer: A Critical Review
por: Chakrabarti, Sakti, et al.
Publicado: (2020)

Tracking longitudinal genetic changes of circulating tumor DNA (ctDNA) in advanced Lung adenocarcinoma treated with chemotherapy
por: Han, Xiaohong, et al.
Publicado: (2019)

Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors
por: Larribère, Lionel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l8b9lgk89iog2sc2tbgs1cc0t9